8-K: Achieve Life Sciences Announces First Quarter 2025 Financial Results and Cytisinicline Program Updates

Achieve Life Sciences reported its Q1 2025 financial results and reiterated its plan to submit a New Drug Application (NDA) for cytisinicline to the FDA in June 2025.

Summary

• Achieve Life Sciences announced its financial results for the first quarter of 2025.
• The company plans to submit an NDA for cytisinicline to the FDA in June 2025.
• The ORCA-3 trial results were published in the Journal of American Medical Association (JAMA) Internal Medicine.
• Key requirements in the ORCA-OL long-term exposure trial were reached, including safety exposure data for 300 participants receiving six months and at least 100 participants receiving one year of cumulative cytisinicline treatment.
• The third safety review of the ORCA-OL clinical trial by the DSMC did not identify any safety concerns.
• A Science Advisory Board (SAB) meeting was conducted with leading experts in nicotine and tobacco cessation research.
• As of March 31, 2025, the company's cash, cash equivalents, and marketable securities were $23.2 million.
• Total operating expenses for the quarter ended March 31, 2025, were $12.9 million.
• Total net loss for the quarter ended March 31, 2025, was $12.8 million.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company is progressing towards a key milestone (NDA submission) and has positive clinical trial data. However, the financial results show a net loss and a decrease in cash reserves, which tempers the overall positive outlook.

Positives

• The company is on track to submit the NDA for cytisinicline to the FDA in June 2025.
• Publication of the ORCA-3 trial results in JAMA Internal Medicine validates cytisinicline as a potential treatment for smoking cessation.
• The ORCA-OL trial met the FDA's long-term exposure requirements, with no safety issues reported.
• The DSMC's review of the ORCA-OL trial showed no unexpected treatment-related adverse events and excellent participant adherence.
• 75% of the 479 participants enrolled in the ORCA-OL trial remain on treatment.

Negatives

• The company reported a net loss of $12.8 million for the first quarter of 2025.
• Operating expenses for the quarter were $12.9 million.
• Cash, cash equivalents, and marketable securities decreased from $34.36 million at the end of 2024 to $23.2 million as of March 31, 2025.

Risks

• The company's success is heavily dependent on the FDA's approval of cytisinicline.
• Achieve may need to obtain additional financing to fund the development and commercialization of cytisinicline.
• New developments in the smoking and vaping cessation landscapes could require changes in business strategy or clinical development plans.
• Macroeconomic and geopolitical conditions, including fluctuating inflation, interest and tariff rates, volatility in the debt and equity markets, actual or perceived instability in the global banking system, global health crises and pandemics and geopolitical conflict could impact the business.

Future Outlook

Achieve Life Sciences plans to submit an NDA for cytisinicline to the FDA in June 2025 and is focused on the development and commercialization of cytisinicline for smoking and vaping cessation.

Management Comments

• Rick Stewart, Chief Executive Officer of Achieve, stated that the NDA submission is a critical inflection point as they move towards delivering the first new FDA-approved treatment for smoking cessation in nearly 20 years.
• Dr. Cindy Jacobs, President and Chief Medical Officer of Achieve, commented that reaching 100 patients with one year of cumulative treatment in the ORCA-OL long-term exposure trial without safety issues further reinforces cytisinicline's tolerability and differentiates it from currently available treatments.

Industry Context

Achieve Life Sciences is focused on addressing the global smoking and nicotine dependence epidemic. The company's cytisinicline is being developed as a potential treatment for smoking and e-cigarette cessation, targeting a market with a significant unmet need for new and effective therapies.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• However, the company's focus on cytisinicline as a novel treatment for nicotine addiction positions it against established pharmaceutical companies with existing smoking cessation products, such as Pfizer (Chantix) and Johnson & Johnson (Nicorette).
• The successful completion of Phase 3 trials and the planned NDA submission are key milestones that will determine its competitive positioning.

Stakeholder Impact

• Positive impact on shareholders with potential FDA approval and commercialization of cytisinicline.
• Potential benefit to public health by providing a new treatment option for smoking cessation.
• Positive impact on patients seeking to quit smoking and vaping.

Next Steps

• Submission of the New Drug Application (NDA) for cytisinicline to the FDA in June 2025.
• Continued development and commercialization of cytisinicline for smoking and vaping cessation.
• Potential FDA review and approval of cytisinicline.

Key Dates

Keywords

cytisinicline, smoking cessation, nicotine dependence, FDA, NDA, ORCA-3, ORCA-OL, clinical trial, Achieve Life Sciences, financial results